Carola Schropp, EBD Group: Partnering is on the up




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Carola Schropp, EBD Group: Partnering is on the up
Released on: October 19, 2012. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Fintan Walton talks to Carola Schropp, President and Founder of the EBD Group
EBD Group's life science partnering and events
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here at BioPharm America, in Boston in 2012. On this show I have Carola Schropp, who is the President of the EBD Group, who actually runs BioPharm America, welcome.
Carola Schropp:
Thank you very much.
Fintan Walton:
Carola, BioPharm America is here in Boston, it's one of your, many conferences you've run not just only here in the US but around the world, so what is happening now in the industry and particularly what you are picking up at this conference?
Carola Schropp:
First of all we are in Boston, because Boston is, or Massachusetts I should say is where things are happening, they are creating lots of jobs here, they are doing a fabulous job supporting the industry, so this is not just a coincidence that we are here.
Fintan Walton:
Right.
Carola Schropp:
Partnering has been growing for quite a few years and it keeps growing. This is what to me is amazing that although there all these voices in the industry saying there is not enough financing, there is not enough this or that, but when it comes down to it partnering is on the up.
Fintan Walton:
Right, now and also the other key thing here is that the nature of partnering is changing and your conferences obviously are important way in which people can network, but the way they network has changed also?
Carola Schropp:
What has happened now, now lets for example take the pharmaceutical side, it used to be that they thought of themselves as you know sitting pretty they were what everybody wanted, right. So they did not have a proactive strategies they were sitting there waiting for people to come to them, they have changed. They now have a very well defined strategy and they are going out to go after projects, they are using their R&D people as scouts, they are bringing in the R&D process much more into the BD world, and I think that's what's different now compared to a few years ago, five-years ago.
Fintan Walton:
Right, so let's look at the operations of EBD Group, because as you said you are here obviously in Boston because it's really important, but you run conferences in Europe, you run conferences in China and so forth. So just in terms of BIO-Europe and the other conferences that you run in Europe, how they are doing are you, have you got the numbers up? Are they going to continue to grow?
Carola Schropp:
Actually it's been amazing, BIO-Europe Spring was up 20% as far as attendees are concerned. I mean this is out of the ballpark, and don't hold me to repeat it for next year. BIO-Europe it looks like we are going to have about 500 people more, so we are going to 3500 if the numbers continue the way they've started.
Opportunities in emerging markets
Fintan Walton:
How important are the emerging markets to this whole drive of partnering?
Carola Schropp:
Emerging markets are very important, but it depends on where you are at. What we hear from pharma is that, let's take China. China is a growing market, but if you think you are going to go there and find new compounds there are not as many as people have expected and this the whole thing has been oversold to a degree which is not to say that they are not there, but things start earlier and it's just more of an issue it's harder than people have thought.
Fintan Walton:
Originally thought?
Carola Schropp:
It's going to be.
Fintan Walton:
Yes, so obviously in China you know it's the early days for innovation, so we can expect that partnering to continue and grow in China?
Carola Schropp:
So the way I would sum up China it's doing well now. The westerners are coming they are checking out what's going on. The Chinese, you know it takes time to approach, for two parties to approach each other. However I believe it will explode in a few years time. Once the Chinese have gotten what it takes, once they know what we are talking about, what the west wants I think they will be doing great.
Fintan Walton:
Okay, so there is China, but also the other emerging markets are like India and Brazil, so what is your observation about those particular territories?
Carola Schropp:
To be honest, I think there is a great opportunity there, but you need to really have a good local network to take advantage of them and we don't have one, so that was different for China but to just go as a western company and try to be successful in India it just takes a lot, you need it's a lot of work.
Web-based partnering services
Fintan Walton:
Right. Okay Carola, the other initiative you've taken is 360 which started about 10 months ago, how is that going?
Carola Schropp:
It's going really well. Would you believe it we have grown from 13,000 people which is the number of people we pre-populated the system with 16,000 in 10 months?
Fintan Walton:
Okay, it's amazing. So the purpose of partnering360 is for people who've attended the conferences in the past to continue to communicate and find out what each other are doing and so they can end up partnering?
Carola Schropp:
That is correct, but we're also are very interested in getting people into the system that are not attending the conferences. The idea is to create something that's useful for the industry and not just have an instrument that's focused on our conferences.
Fintan Walton:
Right, so it's an online networking opportunity?
Carola Schropp:
Exactly, and as far as the conferences are concerned the people who are coming we want them to be able to connect during the time you know between or in-between the conferences.
EBD Group and Inova Software's strategic collaboration
Fintan Walton:
But you've also as part of the package that you are offering to your clients and people who attend those conferences are the opportunity to know more about the deals themselves, so I believe you've just entered into a partnership with a company called Inova , could you tell us about that?
Carola Schropp:
Yes we did, actually you know this was a partnership that's originally driven by demand on the part of pharmaceutical companies?
Fintan Walton:
Right.
Carola Schropp:
Inova has a software, it's called deal tracking software so typically they start once the deal is signed, what the pharmaceutical industry is doing and that relates back to the strategy I mentioned earlier. What they need is, they need to know what's out there hence they are very interested in the data that people are entering into our system, and they have told us that it takes a secretary or an admin whoever for ever and day to copy and paste the information they want away to connect directly to have their system connect to our data.
Fintan Walton:
Under your data is the partnering360" support system?
Carola Schropp:
It's, actually it's more it's the partneringONE", because it's the data that people put into the system that is used for conferences.
Fintan Walton:
Okay, so these are the opportunities this is where people signal what they want and also what they are offering back to the industry, so it's getting that nexus together?
Carola Schropp:
Correct, we are putting, I mean we should have done it from long and we have done it, but it's that the role of the BD person and the research people at big pharma and at biotech to come together to make deals is getting more complex. Think about it, I mean 50, 60% of the drugs that are being approved are not from internal R&D, some people would say, some numbers even say it's more, so deal making is so important and getting increasingly so.
Fintan Walton:
Right, and all the pharmaceutical companies are externalizing their research, in order to do that they need to partner?
Carola Schropp:
Exactly.
Future prospects of EBD Group
Fintan Walton:
Right, so going forward then Carola, what's your, what do you see happening over the next few years?
Carola Schropp:
As I said the activity will increase. I also believe it's that the whole universe is going way beyond biotech and pharma, it's going to be about healthcare, it's I believe in what Ernst &Young calls Pharma 3.0 put the patient in the middle and make him or her the most important focus of what you are doing. Don't worry about the pill, worry about a solution and worry about all the issues you know and work with the diagnostic companies, work with metric devices to do what is needed, what the patient needs to make him or her better.
Fintan Walton:
Okay. Carola, thank you very much indeed for coming on the show.
Carola Schropp:
You are very welcome Fintan.
Fintan Walton
Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Carola Schropp
Founder and President
At the time of this PTV interview Carola Schropp serves as Founder and President of EBD Group. Carola Schropp is Founder and President of EBD Group and widely recognized as one of the original proponents of our global and interconnected bio-economy. Over the past 15 years, Carola has built EBD Group into the leading partnering firm in the life science market. Under her leadership, EBD Group has grown into an organization that today spans five international partnering events on three continents that generate over 30,000 one-to-one meetings annually, and features partnering services for dozens of other events worldwide. In addition to managing the day-to-day operations of the firm, Carola is focused on bringing EBD Group partnering events to new international markets, and developing new services and technologies that foster more collaboration and growth of the biotech industry. She holds a Masters degree in Business Administration (MBA) and an MTS degree, both from Emory University, Atlanta, GA.
PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence &expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialization.
EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since its inception in 1993, EBD Group's mission has been to facilitate the biotech-pharma partnerships that deliver tomorrow's healthcare treatments to patients worldwide. Biotech, pharma and medical device companies actively leverage EBD Group's partnering conferences, technology and services to identify new business opportunities and develop the strategic relationships essential to their future success. EBD Group produces seven of its own landmark partnering events, and provides partnering services for dozens of other industry events. These conferences all feature partneringONE", EBD Group's powerful networking software that takes partnering productivity to a higher level. Executives from across the biotechnology value chain today rely on partneringONE" to efficiently identify new opportunities and start the deal making process through focused one-to-one meetings. By generating over 30,000 such partnering meetings annually, partneringONE" has become an important catalyst for the growth of the bio-economy. Building on this expertise and with unrivaled access to major players in the life science market, EBD Group's consultants provide expert hands-on assistance for firms seeking to in- or out-license products and technologies and develop results-oriented partnering strategies.